Background: Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC. ## Methods: In a multicenter, double-blind, randomized study, 229 patients wit
โฆ LIBER โฆ
S1043 A Direct Comparative Study of Two Different Mesalamine Formulations Revealed Appropriate use of Mesalamine for Patients With Active Ulcerative Colitis Depending on the Characteristics of Disease
โ Scribed by Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Hayato Koyama; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
- Book ID
- 119431609
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 91 KB
- Volume
- 138
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Direct comparison of two different mesal
โ
Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Hidetaka Sasaki; Toy
๐
Article
๐
2010
๐
John Wiley and Sons
๐
English
โ 131 KB
๐ 2 views
Direct comparison of two different mesal
โ
Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Yoshiyuki Aida; Toyo
๐
Article
๐
2010
๐
John Wiley and Sons
๐
English
โ 240 KB
๐ 2 views
Background: Mesalamine has been used as the first-line medication for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two different mesalamine formulations in the maintenance of remission in patients with UC. ## Methods: In a multicenter, double-blind, ran